NatiMab Therapeutics S.r.l.
10010 Colleretto Giacosa (TO), Italy
Prof. Gianni Garotta
NatiMab Therapeutics S.r.l. is a biotechnology company dedicated to the discovery, development and commercialization of human monoclonal antibodies for the therapeutic management of infectious diseases and cancer.
Our fully human antibodies have an advantage over other fully human antibodies because we identify the antibodies out of the B cell repertoire of patients who have acquired immunity to the target of interest. Thus, the antibodies have been selected and matured in the human body and are more likely to have a potent effect in fighting the infection or tumor.
NatiMab was founded in 2008 as a private company registered with the Torino commercial registry (09730260016). The corporate headquarters for NatiMab Therapeutics S.r.l. is located in Colleretto Giacosa (Torino) Italy.
NatiMab has focused its activities on the ENOA (α-Enolase) as a marker for pancreas adenocarcinoma, on the generation of diagnostic test, therapeutic antibodies and/or therapeutic vaccination for pancreas adenocarcinoma.
The assets developed by NatiMab may be licensed out to larger biotech or pharmaceutical companies or co-developed through strategic alliances with such companies.